“ulcerative-colitis” Archives

in
Entry Author Date Location
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D 09/17/20 Boston
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline 09/17/20 Boston
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More 08/14/20 National
Roche Gut Disease Drug Produces Mixed Results in Late-Stage Trials 08/11/20 National
Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 08/10/20 Boston
Two Days, Six IPOs, and $1B Raised for Biotech Research & More 07/17/20 National
Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut 05/20/20 San Francisco
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq 05/15/20 New York
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) 04/22/20 National
Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic 04/01/20 Boston
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch 03/26/20 New York
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome 06/26/19 Boulder/Denver
With Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease 06/10/19 Boston
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes 05/30/19 San Francisco
Flagship Pioneering Unveils Kintai’s Gut Approach to Treating Disease 04/16/19 Boston
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track 03/11/19 New York
Arena’s Comeback Continues with $800M Deal for Lung Disease Drug 11/15/18 San Diego
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More 03/30/18 National
Arena Pharma’s Revamp Gains Traction With New Data For GI Drug 03/20/18 San Diego
FDA Refuses to Review Celgene’s MS Drug, Says File “Insufficient” 02/27/18 New York
Theravance Snares $100M From Janssen in Stomach Drug Deal 02/07/18 San Francisco
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More 10/06/17 National
Protagonist, Janssen Ink Development Deal for Crohn’s Disease Drug 05/30/17 San Francisco
Seres Dissects Failed Microbiome Drug Trial, Suggests Changes to FDA 01/31/17 Boston
Allergan, Eying More Neurodegenerative Drugs, Gets Right to Buy LTI 01/09/17 Boston
Early Data for Celgene’s Oral Crohn’s Drug Gets Mixed Reaction 10/17/16 New York
Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More 10/07/16 National
Celgene Touts Data From Early Study of Oral GI Drug 09/12/16 Boston
Second Genome Replaces DiLaura as CEO, Brings Series B to $51M 07/13/16 San Francisco
PureTech’s Alivio Debuts With Drug-Delivery Gel for Inflammation 05/10/16 Boston
Page 1 of 2 next page »